Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KINE-601B is a synthetic peptide candidate developed by Kine Science for the treatment of alopecia. It is part of the company's proprietary 'Kine-Peptide' platform, which focuses on modulating cell-signaling pathways for regenerative medicine. KINE-601B is designed to target the biological activity of keratinocytes and fibroblasts within the hair follicle environment. By stimulating these cells, the peptide aims to induce regenerative effects that promote hair follicle growth and potentially reverse hair loss. The asset is currently in the early stages of development, specifically in the discovery or preclinical phase, and represents a targeted approach to hair regeneration distinct from traditional hormonal therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KINE-601B.